Comparative efficacy of double plasma molecular adsorption system combined with plasma exchange versus plasma exchange in treating acute‐on‐chronic liver failure due to hepatitis B: A meta‐analysis

This meta‐analysis aims to evaluate the effectiveness of the double plasma molecular adsorption system (DPMAS) in combination with plasma exchange (PE) compared to plasma exchange alone in the treatment of Acute‐on‐Chronic liver failure (LF) caused by hepatitis B. Until August 31, 2023, a comprehens...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical apheresis 2024-08, Vol.39 (4), p.e22140-n/a
Main Authors: Zhang, Le, Ma, Yan, Wang, Xia, Ma, Li‐Na, Ma, Wanlong, Ding, Xiang‐Chun
Format: Article
Language:English
Subjects:
Acute-On-Chronic Liver Failure - blood
Acute-On-Chronic Liver Failure - etiology
Acute-On-Chronic Liver Failure - therapy
Adsorption
Apheresis
artificial liver support
Bilirubin - blood
double plasma molecular adsorption system
Female
Hepatitis B
Hepatitis B - blood
Hepatitis B - complications
Hepatitis B - therapy
Humans
Liver
liver failure
Male
meta‐analysis
Plasma
plasma exchange
Plasma Exchange - instrumentation
Plasma Exchange - methods
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This meta‐analysis aims to evaluate the effectiveness of the double plasma molecular adsorption system (DPMAS) in combination with plasma exchange (PE) compared to plasma exchange alone in the treatment of Acute‐on‐Chronic liver failure (LF) caused by hepatitis B. Until August 31, 2023, a comprehensive search of databases including Embase, Chinese Medical Journal Full‐text Database, China Biomedical Literature Database, Wan Fang Medical Network, PubMed, and the Cochrane Library was carried out using keywords like “liver failure,” “acute‐on‐chronic liver failure,” “PE,” “DPMAS,” and related terms. The quality of the included studies was evaluated using QUADS (quality assessment of diagnostic accuracy studies). Software Revman 5.3 was used to examine the data, while Stata 15.1 was used to run Egger's test. Following thorough screening, 452 patients who received PE alone and 429 patients who received DPMAS in addition to PE were included. Every study that was included was of a high caliber. When comparing the DPMAS plus PE group to the PE alone group, the total bilirubin reduction was considerably higher (mean difference [MD] = −49.09, 95% confidence interval [CI]: −54.84 to −43.35, p 
ISSN:0733-2459
1098-1101
1098-1101
DOI:10.1002/jca.22140